BioSpace News Archive

Contract research organization jobs may not seem as appealing as working in R&D but it can have a lot of advantages—including plenty of career opportunities.

Taiwan Liposome Company, Ltd. announced the signing of a development and license agreement with Birdie Biopharmaceuticals Inc., a wholly owned subsidiary of Seven and Eight Biopharmaceuticals Corp.

We interviewed Georges Belfort, Ph.D., who is an Institute Professor at Rensselaer Polytechnic Institute and Board Chair of the Society for Biological Engineering. In the interview, Dr. Belfort explained the main fields within engineering and how biochemical engineers are unique.

The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company’s long-term reliance on its cash cow, Humira.

Aldeyra Therapeutics reported that its reproxalap failed to meet its primary or secondary endpoints in noninfectious anterior uveitis.

This would appear to be a major step in understanding why and how checkpoint inhibitors work—or don’t work—and will potentially lead to another avenue of research and cancer treatment.

Admedus Ltd announces the publication of an independent study assessing the performance of CardioCel® in the prestigious peer-reviewed journal, The Annals of Thoracic Surgery.

The Management Board of MagForce AG has resolved and successfully completed, with the approval of the Supervisory Board, on basis of the authorization provided for in the Company’s articles of association, an increase of the registerd share capital of the Company from currently EUR 26,463,802.00 to EUR 27,640,274.00 by issuing 1,176,472 new no-par value bearer shares under exclusion of the shareholders’ statutory subscription rights.

Conatus indicated that it is considering a sale of the company as part of an exploration of strategic alternatives. It is already implementing a restructuring plan that will cut 40% of staff and suspend development of its inflammasome compound CTS-2090.

The deal comes as Dermira plans to initiate Phase III studies in the U.S.